By Mariam Sunny March 2 (Reuters) - Pfizer CEO Albert Bourla said the company "has a problem" with the U.S. Food and Drug ...
Good morning. What happens to an organization after it achieves a moonshot? That has been Albert Bourla’s reality, post-COVID. As the CEO of Pfizer, a company he first joined in 1993, Bourla—a ...
Pfizer CEO Albert Bourla joins Squawk on the Street to discuss the company’s up to $10 billion acquisition of Metsera, the competitive landscape in obesity drugs, and Pfizer’s strategy for clinical ...
Hosted on MSN
Pfizer CEO Albert Bourla says aggressive bid for Metsera reflects company's 'right to win' obesity market
Pfizer (PFE) CEO and chairman Albert Bourla told Yahoo Finance Executive Editor Brian Sozzi during Yahoo Finance's annual Invest conference that the $10 billion acquisition of GLP-1 maker Metsera ...
Pfizer’s battle with Novo Nordisk over control of obesity drug developer Metsera is getting nasty. After Pfizer apparently sealed a $4.9 billion purchase of Metsera in September, Novo Nordisk swooped ...
We recently published 12 Stocks on Jim Cramer’s Radar. Pfizer Inc. (NYSE:PFE) is one of the stocks on Jim Cramer's radar. Pfizer Inc. (NYSE:PFE)’s shares are down by 5.90% year-to-date, and December ...
Connecticut-based Pfizer Inc. said Thursday that it has completed the successful acquisition of Metsera, Inc., which is “a clinical-stage biopharmaceutical company accelerating the next generation of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results